News

Analysis from RAND helps frame the potential of biosimilars to reduce spending on biologics.

New data from CMS show that ACOs succeed at producing quality gains and cost savings, but at least one effort begs to differ.

Find out what worked for this value-based physician and hospital network and Accountable Care Organization in Massachusetts.

How can we as an industry help address the growing need and demand for quality mental health services? One of the more promising solutions is the expanded use of certified physician assistants.

Key takeaways for healthcare executives from Bruno Medeiros, MD, associate professor of medicine (hematology) at the Stanford University Medical Center and director of Cancer Center Infusion Area Treatment Services at Stanford Cancer Center.

An Epstein Becker Green survey has surprising results about the expansion of telehealth services physicians and other behavioral health professionals can provide.

One study seeks to understand the underlying causes of racial and ethnic disparities in cancer survival. The results may be surprising.

The success of any value-based care model depends on achieving a strong relationship with members. Here’s three ways how.

While many analyses of Section 1a of the executive order cite doom and gloom for health plans, four tenuous contingencies all must take place in order for this to occur.

Payers’ biggest concerns for 2018, health insurance exchange participation plans, and how offerings could change.

A new study has unbelievable findings about treating Medicare patients with diabetes.

A Robert Wood Johnson Foundation expert analyzes the Altarum Institute’s study on healthcare growth findings.

As genomics continues to evolve, here are five things to know about genetic testing and counseling.

A survey explores how physicians perceive their role in the healthcare system, and the findings aren’t good.

A Physicians Foundation survey gives healthcare executives behind the scenes insight into the physician-patient relationship.

FDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.

With the high efficacy and dire diagnosis, there will be demand for both Kymriah and Yescarta. Here’s how to manage the monetary impact.

CAR-T therapies have high price tags so it’s important to understand your patient population and budget impact.

A University of Massachusetts clinical consulting pharmacist shows how assessing budget implications can be accomplished.

CMS’ 5-Star Rating system requires proactive intervention to improve patient medication adherence, and leaves plans with little room to rest on their laurels.

Pre-drug-approval forecasting and budgeting is increasingly important for payers. Is a safe harbor for manufacturers necessary?

External, non-payer generated data can inform formulary decision-making-if payers know their strengths and weaknesses.

New Yale University research offers stunning findings about drug formulary coverage and prescribing opioids.

One expert says incentive programs to motivate physicians miss the mark. Here’s what he recommends instead.

As the healthcare system shifts from a focus on employee-based plans to consumer-based plans, insurers have to find new ways to engage and motivate members.

Providers are coming up short when it comes to HEDIS measures related to substance abuse. Here’s how one health plan is changing that.

The specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.

Value-based insurance designs for diabetes care improve outcomes, but monetary gains may take years.